Hepion Pharmaceuticals (HEPA)
(Real Time Quote from BATS)
$0.76 USD
-0.26 (-25.49%)
Updated Jul 22, 2024 11:04 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
HEPA 0.76 -0.26(-25.49%)
Will HEPA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HEPA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HEPA
Wall Street Analysts Think Hepion Pharmaceuticals, Inc. (HEPA) Could Surge 674.09%: Read This Before Placing a Bet
Here's Why Hepion Pharma (HEPA) is Up More Than 80% in Two Days
HEPA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for HEPA
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring
Hepion Pharmaceuticals enters merger agreement with Pharma Two B
HEPA Stock Earnings: Hepion Pharmaceuticals Reported Results for Q1 2024
Biotech Alert: Searches spiking for these stocks today